1. Phylogeny  
   ERBB3, also known as HER3, is a member of the ErbB (or HER) family of receptor tyrosine kinases, a group that also includes the epidermal growth factor receptor (EGFR/ErbB1), HER2/ErbB2, and HER4/ErbB4 (jr2004theerbbherreceptor pages 1-2). Orthologs of ERBB3 have been identified in a wide variety of vertebrate species, indicating that the basic framework of ErbB receptor signaling is an evolutionarily conserved feature dating back to early eukaryotes; indeed, the ErbB receptors constitute a prominent branch within the human kinome that emerged via gene duplication events from an ancestral receptor tyrosine kinase (jr2004theerbbherreceptor pages 2-4, jura2011catalyticcontrolin pages 9-11). The evolutionary history of the ErbB family further highlights that, even though all family members share a common domain architecture, ERBB3 evolved with distinctive modifications in its kinase domain. Specifically, compared to its sister receptors, ERBB3 harbors mutations in key catalytic motifs—most notably a replacement of the canonical catalytic aspartate with asparagine in its conserved HRD motif—rendering its intrinsic tyrosine kinase activity severely impaired (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 9-11). Such characteristic differences demarcate ERBB3 not only phylogenetically from other receptor tyrosine kinases with robust catalytic functions but also functionally, as it assumes a predominantly regulatory and scaffolding role in the transduction of extracellular signals. Phylogenetic analyses consistently place ERBB3 within the ErbB subfamily, which is distinguished by the unique mode of ligand- and dimerization-mediated activation and by the evolutionary divergence seen in the intracellular kinase domains (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 9-11). Consequently, ERBB3’s evolutionary position substantiates its role as a crucial modulator of signaling pathways, wherein its conservation across species underscores the essentiality of its function even in the context of diminished catalytic activity (jr2004theerbbherreceptor pages 1-2).
2. Reaction Catalyzed  
   In common with other receptor tyrosine kinases, ERBB3 catalyzes a phosphorylation reaction that transfers the γ-phosphate group from ATP to tyrosine residues present in substrate proteins. The general reaction can be represented as: ATP + [protein]–tyrosine → ADP + [protein]–tyrosine-phosphate + H⁺ (jr2004theerbbherreceptor pages 5-7, sridhar2000proteinkinasesas pages 1-2). Although ERBB3 exhibits markedly reduced intrinsic kinase activity due to substitutions in its catalytic motifs, it nonetheless is capable of autophosphorylation at specific tyrosine residues on its cytoplasmic tail when clustered or activated in a heterodimeric context (shi2010erbb3her3intracellulardomain pages 1-2, jr2004theerbbherreceptor pages 5-7). This phosphorylation reaction, while proceeding at a slower rate relative to fully active kinases such as EGFR, remains functionally significant in the propagation of downstream signaling cascades, particularly those that control cell proliferation and survival (jr2004theerbbherreceptor pages 5-7, shi2010erbb3her3intracellulardomain pages 5-6).
3. Cofactor Requirements  
   As with virtually all protein kinases, the catalytic activity associated with ERBB3 requires ATP as the phosphate donor, and the coordination of ATP binding in the active site is critically dependent on the presence of divalent metal ions. In the case of ERBB3, the cofactor Mg²⁺ is essential for effective coordination of the ATP molecule within the kinase domain, thereby facilitating the phosphotransfer reaction (shi2010erbb3her3intracellulardomain pages 1-2, jr2004theerbbherreceptor pages 5-7). Mg²⁺ ions stabilize the binding of ATP by interacting with its phosphate groups and help lower the activation energy for phosphoryl transfer. This dependence on Mg²⁺ is a hallmark of the catalytic mechanism shared by the protein tyrosine kinase family, despite the impaired catalytic function observed in ERBB3 (wang2014catalyticmechanismsand pages 7-9, sridhar2000proteinkinasesas pages 1-2).
4. Substrate Specificity  
   The substrate specificity of ERBB3 is directed predominantly toward the phosphorylation of tyrosine residues on protein substrates. In fully active receptor tyrosine kinases, specific consensus sequences guide substrate recognition; for ERBB3, although its intrinsic catalytic efficiency is low, the autophosphorylation sites on its cytoplasmic tail exhibit sequence motifs that serve as docking platforms for proteins containing Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains (smith2004emergingrolesof pages 38-39, jr2004theerbbherreceptor pages 4-5). These phosphorylation sites, generated upon heterodimerization with catalytically active partners, particularly ERBB2, are critical for recruiting the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), thereby channeling downstream signals that regulate cell survival and proliferation (smith2004emergingrolesof pages 38-39, cantor2018deepmutationalanalysis pages 10-10). The sequence context surrounding the phosphorylated tyrosine residues, which often contains acidic or hydrophobic amino acid residues at defined positions, contributes to the overall substrate preference of ERBB3 even as its kinase domain functions mainly in a regulatory capacity (yaronbarir2024theintrinsicsubstrate pages 1-2).
5. Structure  
   ERBB3 exhibits a modular architecture that is characteristic of receptor tyrosine kinases. The extracellular portion of ERBB3 is composed of four distinct subdomains that facilitate ligand binding; these domains are arranged to form a platform for the engagement of neuregulin-1 (NRG1) and other ligands (jr2004theerbbherreceptor pages 1-2, smith2004emergingrolesof pages 38-39). Following the extracellular region, ERBB3 possesses a single-pass transmembrane helix that anchors the receptor to the plasma membrane and participates in mediating receptor dimerization. The intracellular region comprises a kinase homology domain followed by a C-terminal tail that contains multiple tyrosine residues targeted for phosphorylation (jr2004theerbbherreceptor pages 1-2, jr2004theerbbherreceptor pages 4-5). Detailed structural studies of the kinase domain reveal that, despite retaining the overall bilobal architecture typical of protein kinases, ERBB3 diverges markedly from fully active kinases. High-resolution crystallographic and ATP analogue-bound models indicate that its kinase domain adopts an “inactive-like” conformation, characterized by a displaced helix αC and a shortened activation loop (shi2010erbb3her3intracellulardomain pages 3-4, endicott2012thestructuralbasis pages 14-16). In addition, crucial catalytic residues such as the aspartate in the HRD motif are replaced by asparagine, contributing to its classification as a pseudokinase (jr2004theerbbherreceptor pages 5-7, shi2010erbb3her3intracellulardomain pages 3-4). These structural peculiarities not only define ERBB3’s impaired ATP turnover but also underscore its reliance on heterodimerization for signal propagation. Moreover, the extracellular region undergoes substantial conformational changes upon ligand binding, including the rotation of specific domains that exposes a dimerization arm essential for receptor-receptor interactions (jr2004theerbbherreceptor pages 4-5, loris2007exploringstructureand pages 43-46). Overall, the unique structural features of ERBB3—ranging from its extracellular ligand-binding domains to its atypical intracellular kinase fold—provide the molecular basis for its specialized regulatory role in cell signaling (jura2011catalyticcontrolin pages 9-11, shi2010erbb3her3intracellulardomain pages 5-6).
6. Regulation  
   The regulation of ERBB3 is primarily achieved through mechanisms of ligand-induced dimerization and subsequent trans-autophosphorylation by partnering with catalytically competent receptors, notably ERBB2 (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 7-8). Binding of neuregulin-1 (NRG1) to the extracellular domain of ERBB3 induces conformational rearrangements that expose the dimerization interface; this structural alteration facilitates the formation of heterodimers, which is a prerequisite for effective signal transduction (jr2004theerbbherreceptor pages 4-5, rauch2011thesecretlife pages 8-9). Once dimerized, the kinase domain of the partner receptor phosphorylates key tyrosine residues located on the C-terminal tail of ERBB3, creating docking sites for a variety of intracellular signaling proteins (smith2004emergingrolesof pages 38-39, shi2010erbb3her3intracellulardomain pages 6-6). Additionally, autophosphorylation events at multiple tyrosine residues, albeit weak when ERBB3 functions in isolation, become significant within the heterodimeric complex; these phosphorylation marks are instrumental in recruiting effectors such as the p85 subunit of PI3K, thereby linking ERBB3 activation to downstream cascades like the PI3K/AKT pathway (smith2004emergingrolesof pages 38-39, cantor2018deepmutationalanalysis pages 9-10). Beyond the immediate effects of ligand binding and phosphorylation, additional regulatory inputs such as receptor internalization, ubiquitination, and feedback inhibition are known to modulate the overall activity and signaling output of the ErbB receptor network (rauch2011thesecretlife pages 22-23, loris2007exploringstructureand pages 149-152). These multilayered regulatory strategies ensure that ERBB3, despite its pseudokinase nature, functions as a tightly controlled signaling node in both developmental and oncogenic contexts (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 9-11).
7. Function  
   Functionally, ERBB3 plays an essential role as a cell surface receptor for neuregulins, particularly neuregulin-1 (NRG1), initiating signaling cascades that govern cellular processes such as growth, differentiation, and survival (jr2004theerbbherreceptor pages 5-7, smith2004emergingrolesof pages 38-39). Upon ligand binding, ERBB3 undergoes dimerization most commonly with ERBB2, a process that is critical for amplifying kinase activity in the heterodimer even though ERBB3 itself is catalytically impaired (jr2004theerbbherreceptor pages 4-5, jura2011catalyticcontrolin pages 15-16). The phosphorylation of tyrosine residues in its C-terminal tail generates specific motifs that serve as binding sites for intracellular adaptor proteins, including the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), which then triggers downstream pathways such as the PI3K/AKT and MAPK cascades (smith2004emergingrolesof pages 38-39, jr2004theerbbherreceptor pages 9-10). This signaling axis is instrumental in promoting cellular proliferation and survival, thereby contributing to tissue development and homeostasis. In addition, ERBB3 has been implicated in the regulation of myeloid cell differentiation, further underscoring its importance in both normal physiological processes and pathological states (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 15-16). The receptor’s ability to participate in heterodimer formation also allows it to integrate signals from diverse extracellular cues, effectively acting as a platform to coordinate cross-talk among multiple signaling pathways (cantor2018deepmutationalanalysis pages 9-10, sridhar2000proteinkinasesas pages 1-2). Thus, although ERBB3’s kinase domain is intrinsically weak, its strategic placement within dimeric receptor complexes enables it to exert significant control over key cellular decisions through allosteric activation and scaffolding functions (jura2011catalyticcontrolin pages 9-11, smith2004emergingrolesof pages 38-39).
8. Other Comments  
   Notwithstanding its impaired kinase activity, ERBB3 remains a prominent target in therapeutic strategies aimed at disrupting aberrant ErbB signaling in cancers. Because ERBB3 functions primarily as a dimerization partner—most notably with ERBB2—therapeutic approaches have focused on targeting its extracellular ligand-binding domain or disrupting heterodimer formation, rather than attempting to inhibit its already low intrinsic catalytic activity (jr2004theerbbherreceptor pages 9-10, shi2010erbb3her3intracellulardomain pages 1-2). Several monoclonal antibodies and small-molecule inhibitors have been developed that target the broader ErbB receptor network, with the goal of attenuating downstream signaling pathways such as PI3K/AKT, which are critical for oncogenic processes (smith2004emergingrolesof pages 38-39, rauch2011thesecretlife pages 22-23). Disease associations of ERBB3 are well documented in various cancers, including breast, colon, and lung malignancies, where upregulation and aberrant activation of ERBB3 contribute to enhanced cell proliferation and survival (jr2004theerbbherreceptor pages 5-7, jura2011catalyticcontrolin pages 15-16). Furthermore, although mutations in the kinase domain of ERBB3 are relatively rare compared to other ErbB family members, alterations that affect receptor dimerization or the spatial arrangement of autophosphorylation sites can significantly impact its signaling output (jura2011catalyticcontrolin pages 14-15, mohanty2016hydrophobiccorevariations pages 16-17). The unique pseudokinase nature of ERBB3, wherein its regulatory role predominates over its catalytic function, positions it as a critical modulator in the ErbB receptor network, inviting continued investigation into more selective inhibitors and novel therapeutic modalities (shi2010erbb3her3intracellulardomain pages 6-6, cantor2018deepmutationalanalysis pages 10-10).
9. References
10. jr2004theerbbherreceptor pages 1-2.
11. jr2004theerbbherreceptor pages 2-4.
12. jr2004theerbbherreceptor pages 4-5.
13. jr2004theerbbherreceptor pages 5-7.
14. jr2004theerbbherreceptor pages 9-10.
15. jura2011catalyticcontrolin pages 7-8.
16. jura2011catalyticcontrolin pages 9-11.
17. jura2011catalyticcontrolin pages 14-15.
18. jura2011catalyticcontrolin pages 15-16.
19. shi2010erbb3her3intracellulardomain pages 1-2.
20. shi2010erbb3her3intracellulardomain pages 3-4.
21. shi2010erbb3her3intracellulardomain pages 4-5.
22. shi2010erbb3her3intracellulardomain pages 5-6.
23. shi2010erbb3her3intracellulardomain pages 6-6.
24. smith2004emergingrolesof pages 38-39.
25. sridhar2000proteinkinasesas pages 1-2.
26. sridhar2000proteinkinasesas pages 2-3.
27. cantor2018deepmutationalanalysis pages 1-1.
28. cantor2018deepmutationalanalysis pages 9-10.
29. fischer2004thedesignof pages 1-2.
30. rauch2011thesecretlife pages 1-2.
31. rauch2011thesecretlife pages 22-23.
32. rauch2011thesecretlife pages 8-9.
33. shah2018thesrcmodule pages 27-28.
34. wang2014catalyticmechanismsand pages 7-9.
35. wang2014catalyticmechanismsand pages 13-15.
36. yaronbarir2024theintrinsicsubstrate pages 1-2.
37. yaronbarir2024theintrinsicsubstrate pages 7-8.
38. kan2023domainarchitectureof pages 16-18.
39. kan2023domainarchitectureof pages 18-20.
40. mohanty2016hydrophobiccorevariations pages 16-17.
41. santos2016paralogspecificpatternsof pages 1-1.

References

1. (jr2004theerbbherreceptor pages 5-7): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.
2. (jura2011catalyticcontrolin pages 9-11): N. Jura, Xuewu Zhang, Nicholas F. Endres, M. Seeliger, T. Schindler, and J. Kuriyan. Catalytic control in the egf receptor and its connection to general kinase regulatory mechanisms. Molecular cell, 42 1:9-22, Apr 2011. URL: https://doi.org/10.1016/j.molcel.2011.03.004, doi:10.1016/j.molcel.2011.03.004. This article has 357 citations and is from a highest quality peer-reviewed journal.
3. (shi2010erbb3her3intracellulardomain pages 1-2): Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, and Mark A. Lemmon. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proceedings of the National Academy of Sciences, 107:7692-7697, Mar 2010. URL: https://doi.org/10.1073/pnas.1002753107, doi:10.1073/pnas.1002753107. This article has 598 citations.
4. (shi2010erbb3her3intracellulardomain pages 3-4): Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, and Mark A. Lemmon. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proceedings of the National Academy of Sciences, 107:7692-7697, Mar 2010. URL: https://doi.org/10.1073/pnas.1002753107, doi:10.1073/pnas.1002753107. This article has 598 citations.
5. (shi2010erbb3her3intracellulardomain pages 4-5): Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, and Mark A. Lemmon. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proceedings of the National Academy of Sciences, 107:7692-7697, Mar 2010. URL: https://doi.org/10.1073/pnas.1002753107, doi:10.1073/pnas.1002753107. This article has 598 citations.
6. (smith2004emergingrolesof pages 38-39): John K. Smith, Naila M. Mamoon, and Roy J. Duhé. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 14:175-225, Jan 2004. URL: https://doi.org/10.3727/000000003772462298, doi:10.3727/000000003772462298. This article has 121 citations.
7. (cantor2018deepmutationalanalysis pages 10-10): Aaron J. Cantor, Neel H. Shah, and John Kuriyan. Deep mutational analysis reveals functional trade-offs in the sequences of egfr autophosphorylation sites. Proceedings of the National Academy of Sciences, 115:E7303-E7312, Jul 2018. URL: https://doi.org/10.1073/pnas.1803598115, doi:10.1073/pnas.1803598115. This article has 39 citations.
8. (endicott2012thestructuralbasis pages 14-16): Jane A. Endicott, Martin E.M. Noble, and Louise N. Johnson. The structural basis for control of eukaryotic protein kinases. Annual Review of Biochemistry, 81:587-613, Jul 2012. URL: https://doi.org/10.1146/annurev-biochem-052410-090317, doi:10.1146/annurev-biochem-052410-090317. This article has 524 citations and is from a domain leading peer-reviewed journal.
9. (jr2004theerbbherreceptor pages 1-2): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.
10. (jr2004theerbbherreceptor pages 2-4): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.
11. (jr2004theerbbherreceptor pages 4-5): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.
12. (jr2004theerbbherreceptor pages 9-10): R Roskoski Jr. The erbb/her receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications, 319 1:1-11, Jun 2004. URL: https://doi.org/10.1016/j.bbrc.2004.04.150, doi:10.1016/j.bbrc.2004.04.150. This article has 628 citations and is from a peer-reviewed journal.
13. (jura2011catalyticcontrolin pages 15-16): N. Jura, Xuewu Zhang, Nicholas F. Endres, M. Seeliger, T. Schindler, and J. Kuriyan. Catalytic control in the egf receptor and its connection to general kinase regulatory mechanisms. Molecular cell, 42 1:9-22, Apr 2011. URL: https://doi.org/10.1016/j.molcel.2011.03.004, doi:10.1016/j.molcel.2011.03.004. This article has 357 citations and is from a highest quality peer-reviewed journal.
14. (loris2007exploringstructureand pages 149-152): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
15. (loris2007exploringstructureand pages 43-46): M Loris. Exploring structure and plasticity of tyrosine kinase domains for drug discovery. Unknown journal, 2007.
16. (shi2010erbb3her3intracellulardomain pages 5-6): Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, and Mark A. Lemmon. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proceedings of the National Academy of Sciences, 107:7692-7697, Mar 2010. URL: https://doi.org/10.1073/pnas.1002753107, doi:10.1073/pnas.1002753107. This article has 598 citations.
17. (shi2010erbb3her3intracellulardomain pages 6-6): Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, and Mark A. Lemmon. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proceedings of the National Academy of Sciences, 107:7692-7697, Mar 2010. URL: https://doi.org/10.1073/pnas.1002753107, doi:10.1073/pnas.1002753107. This article has 598 citations.
18. (sridhar2000proteinkinasesas pages 1-2): Rajagopalan Sridhar, Olivia Hanson‐Painton, and Denise R. Cooper. Protein kinases as therapeutic targets. Pharmaceutical Research, 17:1345-1353, Nov 2000. URL: https://doi.org/10.1023/a:1007507224529, doi:10.1023/a:1007507224529. This article has 118 citations and is from a domain leading peer-reviewed journal.
19. (sridhar2000proteinkinasesas pages 2-3): Rajagopalan Sridhar, Olivia Hanson‐Painton, and Denise R. Cooper. Protein kinases as therapeutic targets. Pharmaceutical Research, 17:1345-1353, Nov 2000. URL: https://doi.org/10.1023/a:1007507224529, doi:10.1023/a:1007507224529. This article has 118 citations and is from a domain leading peer-reviewed journal.
20. (yaronbarir2024theintrinsicsubstrate pages 1-2): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 56 citations and is from a highest quality peer-reviewed journal.
21. (cantor2018deepmutationalanalysis pages 1-1): Aaron J. Cantor, Neel H. Shah, and John Kuriyan. Deep mutational analysis reveals functional trade-offs in the sequences of egfr autophosphorylation sites. Proceedings of the National Academy of Sciences, 115:E7303-E7312, Jul 2018. URL: https://doi.org/10.1073/pnas.1803598115, doi:10.1073/pnas.1803598115. This article has 39 citations.
22. (cantor2018deepmutationalanalysis pages 9-10): Aaron J. Cantor, Neel H. Shah, and John Kuriyan. Deep mutational analysis reveals functional trade-offs in the sequences of egfr autophosphorylation sites. Proceedings of the National Academy of Sciences, 115:E7303-E7312, Jul 2018. URL: https://doi.org/10.1073/pnas.1803598115, doi:10.1073/pnas.1803598115. This article has 39 citations.
23. (fischer2004thedesignof pages 1-2): PM Fischer. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry, 11:1563-1583, Jun 2004. URL: https://doi.org/10.2174/0929867043365062, doi:10.2174/0929867043365062. This article has 160 citations and is from a peer-reviewed journal.
24. (jura2011catalyticcontrolin pages 14-15): N. Jura, Xuewu Zhang, Nicholas F. Endres, M. Seeliger, T. Schindler, and J. Kuriyan. Catalytic control in the egf receptor and its connection to general kinase regulatory mechanisms. Molecular cell, 42 1:9-22, Apr 2011. URL: https://doi.org/10.1016/j.molcel.2011.03.004, doi:10.1016/j.molcel.2011.03.004. This article has 357 citations and is from a highest quality peer-reviewed journal.
25. (jura2011catalyticcontrolin pages 7-8): N. Jura, Xuewu Zhang, Nicholas F. Endres, M. Seeliger, T. Schindler, and J. Kuriyan. Catalytic control in the egf receptor and its connection to general kinase regulatory mechanisms. Molecular cell, 42 1:9-22, Apr 2011. URL: https://doi.org/10.1016/j.molcel.2011.03.004, doi:10.1016/j.molcel.2011.03.004. This article has 357 citations and is from a highest quality peer-reviewed journal.
26. (rauch2011thesecretlife pages 1-2): Jens Rauch, Natalia Volinsky, David Romano, and Walter Kolch. The secret life of kinases: functions beyond catalysis. Cell Communication and Signaling : CCS, 9:23-23, Oct 2011. URL: https://doi.org/10.1186/1478-811x-9-23, doi:10.1186/1478-811x-9-23. This article has 243 citations.
27. (rauch2011thesecretlife pages 22-23): Jens Rauch, Natalia Volinsky, David Romano, and Walter Kolch. The secret life of kinases: functions beyond catalysis. Cell Communication and Signaling : CCS, 9:23-23, Oct 2011. URL: https://doi.org/10.1186/1478-811x-9-23, doi:10.1186/1478-811x-9-23. This article has 243 citations.
28. (rauch2011thesecretlife pages 8-9): Jens Rauch, Natalia Volinsky, David Romano, and Walter Kolch. The secret life of kinases: functions beyond catalysis. Cell Communication and Signaling : CCS, 9:23-23, Oct 2011. URL: https://doi.org/10.1186/1478-811x-9-23, doi:10.1186/1478-811x-9-23. This article has 243 citations.
29. (shah2018thesrcmodule pages 27-28): Neel H. Shah, Jeanine F. Amacher, Laura M. Nocka, and John Kuriyan. The src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Critical Reviews in Biochemistry and Molecular Biology, 53:535-563, Sep 2018. URL: https://doi.org/10.1080/10409238.2018.1495173, doi:10.1080/10409238.2018.1495173. This article has 93 citations and is from a peer-reviewed journal.
30. (wang2014catalyticmechanismsand pages 13-15): Zhihong Wang and Philip A. Cole. Catalytic mechanisms and regulation of protein kinases. Methods in Enzymology, pages 1-21, Jan 2014. URL: https://doi.org/10.1016/b978-0-12-397918-6.00001-x, doi:10.1016/b978-0-12-397918-6.00001-x. This article has 225 citations and is from a peer-reviewed journal.
31. (wang2014catalyticmechanismsand pages 7-9): Zhihong Wang and Philip A. Cole. Catalytic mechanisms and regulation of protein kinases. Methods in Enzymology, pages 1-21, Jan 2014. URL: https://doi.org/10.1016/b978-0-12-397918-6.00001-x, doi:10.1016/b978-0-12-397918-6.00001-x. This article has 225 citations and is from a peer-reviewed journal.
32. (yaronbarir2024theintrinsicsubstrate pages 7-8): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 56 citations and is from a highest quality peer-reviewed journal.
33. (kan2023domainarchitectureof pages 16-18): Yagmur Kan, YiTing Paung, Markus A. Seeliger, and W. Todd Miller. Domain architecture of the nonreceptor tyrosine kinase ack1. Cells, 12:900, Mar 2023. URL: https://doi.org/10.3390/cells12060900, doi:10.3390/cells12060900. This article has 5 citations and is from a peer-reviewed journal.
34. (kan2023domainarchitectureof pages 18-20): Yagmur Kan, YiTing Paung, Markus A. Seeliger, and W. Todd Miller. Domain architecture of the nonreceptor tyrosine kinase ack1. Cells, 12:900, Mar 2023. URL: https://doi.org/10.3390/cells12060900, doi:10.3390/cells12060900. This article has 5 citations and is from a peer-reviewed journal.
35. (mohanty2016hydrophobiccorevariations pages 16-17): Smita Mohanty, Krishnadev Oruganty, Annie Kwon, Dominic P. Byrne, Samantha Ferries, Zheng Ruan, Laura E. Hanold, Samiksha Katiyar, Eileen J. Kennedy, Patrick A. Eyers, and Natarajan Kannan. Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization. PLOS Genetics, 12:e1005885, Feb 2016. URL: https://doi.org/10.1371/journal.pgen.1005885, doi:10.1371/journal.pgen.1005885. This article has 42 citations and is from a domain leading peer-reviewed journal.
36. (santos2016paralogspecificpatternsof pages 1-1): Helena G. Dos Santos and Jessica Siltberg-Liberles. Paralog-specific patterns of structural disorder and phosphorylation in the vertebrate sh3–sh2–tyrosine kinase protein family. Genome Biology and Evolution, 8:2806-2825, Aug 2016. URL: https://doi.org/10.1093/gbe/evw194, doi:10.1093/gbe/evw194. This article has 9 citations and is from a domain leading peer-reviewed journal.